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Abstract
Introduction: There is substantial variation in the clinical
characteristics and outcomes of severe coronavirus disease
(COVID-19), making it difficult to do an optimal assessment
of this condition. We reviewed the current English literature
to identify the findings concerning the baseline characteristics and health outcomes of patients with severe COVID19, primarily those with acute respiratory distress syndrome
(ARDS).
Methods: We examined only studies that assessed patients with confirmed COVID-19 by reverse transcriptionpolymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with at least
one of the following severity criteria: treated in the intensive
care unit (ICU), ARDS, and/or invasive mechanical ventilation
(IMV) treatment. We assessed the quality of the studies according to the National Heart, Lung and Blood Institute study
quality assessment tools.
Results: Seven of 39 studies fulfilled the inclusion criteria.
These seven studies included a total 1,863 patients; the me-

Introduction
The new severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) is the cause of the coronavirus disease-19 (COVID-19) and it was originally
reported in Wuhan, China in December 2019. Today
this unprecedented COVID-19 pandemic spread to the
whole globe resulting in about 7,500,000 infected people and the loss of about 430,000 humans lives.[1] In
relation to the severity of illness, COVID-19 has a spectrum of clinical presentations. Severe COVID-19 has
been reported in about 14 % of patients with a fatality
rate of 49%.[2] In the time of severe COVID-19 leading
to an unexpectedly high number of deaths, it is important to examine history to reassure our best approaches
to a new problem. Though severe COVID-19 is new
for us, similar epidemics happened over time. In this
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dian age was 63.5 years (range 49–70). A total 370 (19.8%)
were females. Four studies were from the USA, two from
China and one from Italy. Comorbidities were reported in six
studies. Fever was reported in five studies and was present
in 159 out of 272 patients. Cough and shortness of breath
(SOB) were reported in four studies, present in 111 out of
142 and 100 out of 142 patients, respectively. The median
total lymphocytes was reported in five studies with a range
of 400–889/ul. IMV ranged from 15% to 100%, and mortality ranged from 14.6% to 88%. In a subgroup analysis by
country, patients from the US showed more comorbidities and
higher percentages of IMV and mortality. The mean assessment quality score of the seven studies was 5 out of a maximum 9.
Conclusions: Severe COVID-19 was predominantly seen in
male patients who were 60 years or older and was associated
with comorbidities. Most of the patients were admitted to the
ICU and needed IMV support due to ARDS, and the overall
mortality rate had a range of 14.6–88%.

regard, the historical quote the “Captain of the Men
of Death” which was originally coined by John Bunyan for tuberculosis is very timely and wise to relate
to severe COVID-19.[3] It is tempting to conceive that
COVID-19 is the current Captain of Death.
It is important to highlight the exponential health care
burden, morbidity, and mortality of severe COVID-19.
The American Hospital Association estimates a total
four-month financial impact of $202.6 billion in losses
for America’s hospitals and health systems, or an average of $50.7 billion per month.[4] The UN’s Trade and
Development Agency says the slowdown in the global
economy caused by the coronavirus outbreak is likely
to cost at least $1 trillion.[5]
There are substantial variabilities of the clinical characteristics and outcomes of severe COVID-19, which
1
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creates difficulty in doing an optimal assessment of
this condition. Though severe COVID-19 has been reported to present as septic shock, acute cardiac complication, stroke and involving many other organs; there
is increasing evidence that the lung involvement resulting in ARDS is the most common and fatal complication.[6] The objective of the study is to review the current English literature to quantify the findings of clinical presentation and health outcomes of patients with
severe COVID-19 primarily with acute respiratory distress syndrome (ARDS).

Methods
Database search strategies
We did a search in PubMed and Google Scholar using
the queries “COVID-19”, “Severe COVID-19”, “Clinical Characteristics” and “Clinical Outcomes”.
Inclusion criteria
Studies that assessed patients with proven COVID-19
by RT-PCR for SARS-CoV-2. These studies examined
and provided data of patients with severe COVID-19,
patients treated in the ICUs, patients with the diagnosis of ARDS and patients who were receiving treatment
with invasive mechanical ventilation.
Exclusion criteria
Studies that did not include cases according to the inclusion criteria. Studies that claimed including cases
according to our inclusion criteria, but they did not provide baseline clinical characteristics and outcomes.
Quality assessment
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cases were not severe COVID-19.[8] Therefore, there
were seven publications for our review.[2, 9-14]
Total severe COVID-19 cases included by gender and age
Our study included a total 1,863 patients, the median
age was 63.5 years and range was 49–70 years. A total
370 (19.8%) were females. Four studies were from the
USA, two from China and one from Italy.[2, 9-14]
Reported comorbidities
The comorbidities reported in six studies were as follows: diabetes mellitus 254 (13.6%), arterial hypertension 604/1818 (33.2%), chronic obstructive pulmonary
disease (COPD) 58/1779 (3.3%), chronic kidney disease
(CKD) 51/1636 (3.1%).
Clinical symptoms
Fever was reported in five studies and it was reported
to be present in 159 out of 272 patients included in the
five studies. Cough and shortness of breath (SOB) were
reported in four studies. In these four studies, cough
was present in 111 out of 142 patients and SOB in 100
out of 142. None of the study reported vomiting and
diarrhea.
Laboratory studies
The median of total lymphocytes was reported in five
studies with a range of 400 – 889/ul. The arterial
partial pressure of oxygen/fraction of inspired oxygen
(PaO2/FiO2) ratio was reported in three studies with a
range of 69-492 (median 160).
Imaging studies

We assessed the quality of the studies according to the
National Heart, Lung and Blood Institute, Study Quality Assessment Tools.[7]

Imaging studies were reported only in four studies. Bilateral lung infiltrates in chest X-ray were reported in
161 out of 188 (85.6%) patients and ground-glass opacities (GGO) on computerized tomography (CT) in 15 out
of 45 patients (33.3%).

Results

Outcomes

Selected publications

Baseline outcomes are depicted in Table 1.

Our search in the databases PubMed and Google
Scholar revealed 39 publications. A total 32 publications were excluded according to the exclusion criteria
and we selected eight publications for our review. Subsequently, a publication that reported assessing severe
COVID-19 was eliminated because the reported findings were not consistent with severe COVID-19. This
study reported A-a gradient for the non-severe and severe COVID-19 of 3.9 vs. 4.0 respectively. These reported severe cases showed a rate of ARDS of 15.6%,
intensive care unit (ICU) admission of 19.1% and a mortality of 8.1%. This clearly indicates that most of these

Comparison of baseline clinical characteristics and outcomes
in patients from USA and China
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To find out whether the type of medical practice and
patient population by country could have influenced
the clinical characteristics and outcomes, we compared
the cases of severe COVID-19 by country. In this comparison, patients reported in the US showed more comorbidities more often, higher percent of IMV and
mortality than those from China (Table 2a and Table
2b).
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Table 1. Baseline characteristics and outcomes of patients with severe COVID-19.
Study

Clinical characteristics

Outcomes

Grasselli et al.[10]

Median age 63 years

Mortality 26%

Journal: JAMA

Female 18%

IMV 88%

Number of patients: 1,591

DM 17%, HTN 49%, COPD 4%, CKD 3%

Severity criteria: ICU admission

PaO2/FiO2 median 160

Country: Italy
Arentz et al.[11]

Median age 70 years

Mortality 52.4%

Journal: JAMA

Female 48%

IMV 71%

Number of patients: 21

DM 33.3%, COPD 33.3%, CHF 42.9%, CKD 47.6%

Severity criteria: ICU admission

Fever 52%, SOB 76%

Country: USA

Total lymphocyte 889/ul PaO2/FiO2 ratio 169

Bhatraju et al.[12]

Mean age 64±18 (23–97) years

Mortality 50%

Journal: NEJM

Female 38%

IMV 75%

Number of patients: 24

DM 58%, CKD 21%, COPD 4%

Severity criteria: ICU admission

Fever 50%, SOB 88%

Country: USA

Total lymphocytes 720/ul

CXR lung infiltrates 52%, b/l GGO 48%

CXR lung infiltrates 100%, CT GGO 80%
Huang et al.[13]

Median age 49 years

Journal: Lancet

Female 15%

Mortality 38%
ARDS 85%

Number of patients: 13

DM 8%, HTN 15%, COPD 8%, CVD 23%

IMV 15%

Severity criteria: ICU admission

Fever 100%, SOB 92%

NIMV 62%

Country: China

Total lymphocytes 400/ul, D-dimer 2.4 mg/L

Septic shock 23%

CXR lung infiltrates 100%

Cardiac injury 31%

Wu et al.[2]

Median age 58.5 years

AKI 23%
Mortality 47.6%

Journal: JAMA IM

Female 28.6%

ICU 26.6%

Number of patients: 84

DM 19%, HTN 27.4%

ARDS 41.8%

Severity criteria: ARDS

Fever 92.9%, SOB 59.5%, cough 81%

IMV 21.3%

Country: China

Total lymphocytes 670/ul
CRP 83
D-dimer 1.16 mg/L

Goyal et al.[14]

Median age 64.5 years

Journal: NEJM

Female 29.2%

Number of patients: 130

DM 27.7%, HTN 70 53.8%, COPD 5.4%

Severity criteria: IMV

Fever 34.6%

Country: USA

CXR lung infiltrates 87.7%

Richardson et al.[9]

Total lymphocytes 800/ul

Mortality 14.6%

Mortality 88%

Journal: JAMA

IMV 320/373, 85.7%

Number of patients: 373

Mortality in IMV 282/230, 88%

Severity criteria: ICU admission
Country: USA
Abbreviations: AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; CHF, congestive heart failure; CKD,
chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CT, computerized tomography; CVD, cardiovascular disease; CXR, chest X-ray; DM, diabetes mellitus; GGO, ground-glass opacities; HTN, hypertension; ICU, intensive care unit; IMV, invasive mechanical ventilation; NIMV, noninvasive mechanical ventilation; PaO2/FiO2,
arterial partial pressure of oxygen/fraction of inspired oxygen; SOB, shortness of breath.
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Table 2. Baseline characteristics and outcomes of patients with severe COVID-19 by country.
a) Studies from the USA.
Study

Clinical characteristics

Outcomes

Arentz et al.[11]

Median age 70 years

Mortality 52.4%

Journal: JAMA

Female 48%

IMV 71%

Number of patients: 21

DM 33.3%, COPD 33.3%, CHF 42.9%, CKD 47.6%

Severity criteria: ICU admission

Fever 52%, SOB 76%

Country: USA

Total lymphocyte 889/ul PaO2/FiO2 ratio 169

Bhatraju et al.[12]

Mean age 64±18 (23–97) years

Mortality 50%

Journal: NEJM

Female 38%

IMV 75%

Number of patients: 24

DM 58%, CKD 21%, COPD 4%

Severity criteria: ICU admission

Fever 50%, SOB 88%

Country: USA

Total lymphocytes 720/ul

CXR lung infiltrates 52%, b/l GGO 48%

CXR lung infiltrates 100%, CT GGO 80%
Goyal et al.[14]

Median age 64.5 years

Journal: NEJM

Female 29.2%

Number of patients: 130

DM 27.7%, HTN 70 53.8%, COPD 5.4%

Severity criteria: IMV

Fever 34.6%

Country: USA

CXR lung infiltrates 87.7%

Richardson et al.[9]

Total lymphocytes 800/ul

Mortality 14.6%

Mortality 88%

Journal: JAMA

IMV 320/373, 85.7%

Number of patients: 373

Mortality in IMV 282/230, 88%

Severity criteria: ICU admission
Country: USA
b) Studies from China.
Study

Clinical characteristics

Outcomes

Huang et al.[13]

Median age 49 years

Mortality 38%

Journal: Lancet

Female 15%

ARDS 85%

Number of patients: 13

DM 8%, HTN 15%, COPD 8%, CVD 23%

IMV 15%

Severity criteria: ICU admission

Fever 100%, SOB 92%

NIMV 62%

Country: China

Total lymphocytes 400/ul, D-dimer 2.4 mg/L

Septic shock 23%

CXR lung infiltrates 100%

Cardiac injury 31%

Wu et al.[2]

Median age 58.5 years

AKI 23%
Mortality 47.6%

Journal: JAMA IM

Female 28.6%

ICU 26.6%

Number of patients: 84

DM 19%, HTN 27.4%

ARDS 41.8%

Severity criteria: ARDS

Fever 92.9%, SOB 59.5%, cough 81%

IMV 21.3%

Country: China

Total lymphocytes 670/ul
CRP 83
D-dimer 1.16 mg/L

Abbreviations: AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CT, computerized tomography; CVD, cardiovascular disease;
CXR, chest X-ray; DM, diabetes mellitus; GGO, ground-glass opacities; HTN, hypertension; ICU, intensive care unit; IMV, invasive mechanical
ventilation; NIMV, noninvasive mechanical ventilation; PaO2/FiO2, arterial partial pressure of oxygen/fraction of inspired oxygen; SOB, shortness
of breath.
ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/55

4

ULJRI

Severe COVID-19

Table 3. Quality assessment of studies of severe COVID-19.
Grasselli,
et al.[10]
JAMA

Arentz et
al.[11]
JAMA

Bhatraju
et al.[12]
NEJM

Huang et
al.[13]
Lancet

Wu et
al.[2]
JAMA IM

Goyal et
al.[14]
NEJM

Richardson
et al.[9]
JAMA

1. Was the study question or objective
clearly stated?

1

1

1

1

1

1

1

2. Was the study population clearly and
fully described, including a case
definition?

1

1

1

1

1

1

1

3. Were the cases consecutive?

CD

CD

CD

CD

CD

CD

CD

4. Were the subjects comparable?

NR

NR

NR

NR

NR

NR

NR

5. Was the intervention clearly described?

NA

NA

NA

l

NA

NA

NA

6. Were the outcome measures clearly
defined, valid, reliable, and implemented
consistently across all study participants?

1

1

1

1

1

0

1

7. Was the length of follow-up adequate?

1

0

1

0

1

1

1

8. Were the statistical methods welldescribed?

1

0

1

1

0

0

1

9. Were the results well-described?

1

1

1

1

1

0

1

Score∗ :

6

4

6

5

5

3

6

/9

Abbreviations: CD, cannot determine; NA, not applicable; NR, not reported.
∗ Yes=1, No=0.

Assessment of data quality
The mean assessment of data quality score for the seven
studies was 5 out of a maximum 9 (Table 3).

Discussion
Our study examined seven studies addressing severe
COVID-19 with an average quality score of 5 out of
8 points. These seven studies showed a substantial
variability of the clinical characteristics and outcomes
of patients with severe COVID-19. Severe COVID 19
was seen predominantly in males; six of the studies
showed a range of 15% - 48% of females and an average of 29.5% female.[2,10-14] It means; less than 1 out
of 5 patients with severe COVID-19 will be a woman.
At the best interpretation of 4 out of 6 studies that provided the patients ages, the patients median age was
64 years and older.[10-12,14] Six of the studies revealed
multiple comorbidities.[2,10-14] Diabetes mellitus, arterial hypertension and COPD were the most reported
comorbidities.
The angiotensin converting enzyme (ACE)-2 has been
established to play an essential role in preventing the
development of the toxic inflammatory response in
COVID-19.[15] Furthermore, ACE-2 was reported to
decrease with aging and to have a lower expression in
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males.[16] The latter is related to the fact that the ACE-2
genes map to the X chromosome.[17] Similarly, ACE-2
is expressed less in patients with comorbidities.[15] In
line with these specific distributions of the expression
of the ACE-2, elderly male patients with comorbidities are expected to be the main patients with severe
COVID-19 as reported by the studies in our review.
An important finding of our review is that fever was
not very common among patients with severe COVID19. Fever was common in studies reported in China
and these studies have a lower mortality.[2,13] This observation is in line with the statement that fever is a
marker of optimal host response to an injury. Interestingly, some studies showed that fever was present
in only about 50% of patients and the same studies
revealed a mortality of about 50%.[2,13] It could be
speculated that patients without fever were severely
ill and had a poor host response resulting in death.
Lymphopenia is a common laboratory marker of severe COVID-19 and it is being considered a major factor in the pathogenesis and mechanisms of the severity of COVID-19.[18] Severe COVID-19 has been associated with a cytokine release storm largely related to the
ACE-2. The ACE-2 is found in many cells of different
organs. ACE converts angiotensin-I into angiotensin-II,
which through the angiotensin type-1 receptor (AT-1R),
triggers vasoconstriction, inflammation, and thrombosis.[15] On the other hand, ACE-2 converts angiotensin
5
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II into angiotensin 1-7, which binds to angiotensin type
2 receptor (AT-2R) triggering vasodilation, less fibrosis
and less thrombosis. Thus, ACE-2 is a master regulator
of the renin-angiotensin system (RAS) by converting
angiotensin I and angiotensin II to 1-9 and 1-7 respectively. Because ACE-2 is the receptor of SARS-CoV-2,
upon the virus binds to ACE-2, the counter regulation
activity of ACE-2 over renin-angiotensin system (RAS)
is lost.
Our study has some weaknesses and strengths. Some
of the weaknesses are related to the few numbers of
studies, the quality of the studies, lack of standardization of baseline characteristics, and outcomes. All
these factors resulted in an important variability of
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the characteristics and outcomes of patients with severe COVID-19. Many of the weaknesses are acceptable in view of the urgent need to report data of severe
COVID-19. The strength of our review study is that according to our knowledge this is the first review study
on severe COVID-19.
In conclusion, severe COVID-19 was predominantly
seen in male patients aged 60 years and older associated mostly with diabetes mellitus, arterial hypertension, and COPD. Fever seems to be present in a half of
the patients and more often SOB. Most of the patients
were admitted at the ICU, needed IMV support due to
ARDS and had a mortality range of 14.6–88%.

distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.

Published: July 27, 2020
Copyright: © 2022 The author(s). This original article is
brought to you for free and open access by ThinkIR: The University of Louisville’s Institutional Repository. For more information, please contact thinkir@louisville.edu. This article is

Funding Source: The author(s) received no specific funding
for this work.
Conflict of Interest: All authors declared no conflict of interest in relation to the main objective of this work.

References
1. Johns Hopkins University Center for Systems Science and
Engineering. COVID-19 dashboard. Available at: https:
//coronavirus.jhu.edu/map.html. Accessed 26 June 2020.
2. Wu C, Chen X, Cai Y, et al. Risk factors associated with
acute respiratory distress syndrome and death in patients
with coronavirus disease 2019 pneumonia in Wuhan, China.
JAMA Intern Med 2020; 180(7):934-43. doi: 10.1001/jamainternmed.2020.0994. PMID: 32167524.
3. Osler W. The principles and practice of medicine : Designed for the use of practitioners and students of medicine.
New York: D. Appleton and Company, 1892.
4. American Hospital Association. Hospitals and health systems face unprecedented financial pressures due to COVID19. Available at: https://www.aha.org/guidesreports/202005-05-hospitals-and-health-systems-face-unprecedentedfinancial-pressures-due. Accessed 5 May 2020.
5. United Nations. This is how much the coronavirus will cost
the world’s economy, according to the UN. Available at: https:
//www.weforum.org/agenda/2020/03/coronavirus-covid-19cost-economy-2020-un-trade-economics-pandemic.
Accessed 3 May 2020.
6. Berlin DA, Gulick RM, Martinez FJ. Severe COVID-19.
N Engl J Med 2020; 383(25):2451-60. doi: 10.1056/NEJMcp2009575. PMID: 32412710.
7. National Heart, Lung, and Blood Institute.
Available at: https://www.nhlbi.nih.gov/health-topics/study-qualityassessment-tools. Accessed 27 May 2020.
ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/55

8. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of
coronavirus disease 2019 in China. N Engl J Med 2020;
382(18):1708-20. doi: 10.1056/NEJMoa2002032. PMID:
32109013.
9. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting
characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area.
JAMA 2020; 323(20):2052-9. doi: 10.1001/jama.2020.6775.
PMID: 32320003.
10. Grasselli G, Zangrillo A, Zanella A, et al. Baseline
characteristics and outcomes of 1,591 patients infected with
SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy.
JAMA 2020; 323(16):1574-81. doi: 10.1001/jama.2020.5394.
PMID: 32250385.
11. Arentz M, Yim E, Klaff L, et al. Characteristics and
outcomes of 21 critically ill patients with COVID-19 in
Washington State.
JAMA 2020; 323(16):1612-4.
doi:
10.1001/jama.2020.4326. PMID: 32191259.
12. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. COVID19 in critically ill patients in the Seattle region - case series.
N Engl J Med 2020; 382(21):2012-22. doi: 10.1056/NEJMoa2004500. PMID: 32227758.
13. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet 2020; 395(10223):497-506. doi: 10.1016/s01406736(20)30183-5. PMID: 31986264.

6

ULJRI
14. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of COVID-19 in New York City. N Engl J Med
2020; 382(24):2372-4. doi: 10.1056/NEJMc2010419. PMID:
32302078.
15. Gheblawi M, Wang K, Viveiros A, et al. Angiotensinconverting enzyme 2: SARS-CoV-2 receptor and regulator of
the renin-angiotensin system: Celebrating the 20th anniversary of the discovery of ACE2. Circ Res 2020; 126(10):145674. doi: 10.1161/circresaha.120.317015. PMID: 32264791.
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